These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36167856)

  • 1. Neutralization Activity of Anti-drug Antibodies Against a Biotherapeutic Can Be Predicted from a Comprehensive Pharmacokinetics, Pharmacodynamics, and Anti-drug Antibody Data Analysis.
    Xu W; Maas B; Roadcap B; Swarup A; Steinmetz T; Luo L; Ichetovkin M; Wood S; Vazvaei-Smith F; Lee AW; Vora K; Helmy R
    AAPS J; 2022 Sep; 24(6):102. PubMed ID: 36167856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays.
    Xu W; Jiang H; Titsch C; Haulenbeek JR; Pillutla RC; Aubry AF; DeSilva BS; Arnold ME; Zeng J; Dodge RW
    J Immunol Methods; 2015 Jan; 416():94-104. PubMed ID: 25445325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Cell-Based Assay for the Detection of Neutralizing Antibodies to PF-06730512 Using Homogenous Time-Resolved Fluorescence.
    Luong M; Wang Y; Berasi SP; Buhlmann JE; Yang H; Gorovits B
    AAPS J; 2020 Mar; 22(2):56. PubMed ID: 32166588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bead-extraction and heat-dissociation (BEHD): A novel way to overcome drug and matrix interference in immunogenicity testing.
    Xu W; Sank M; Cummings J; Carl S; Juhel M; Gleason C; Dodge R; DeSilva BS; Kolaitis G; Pillutla R
    J Immunol Methods; 2018 Nov; 462():34-41. PubMed ID: 30099014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.
    Wyant T; Yang L; Rosario M
    AAPS J; 2020 Nov; 23(1):3. PubMed ID: 33200296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative use of LC-MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development.
    Jiang H; Xu W; Titsch CA; Furlong MT; Dodge R; Voronin K; Allentoff A; Zeng J; Aubry AF; DeSilva BS; Arnold ME
    Anal Chem; 2014 Mar; 86(5):2673-80. PubMed ID: 24506335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure.
    Lotz GP; Lutz A; Martin-Facklam M; Hansbauer A; Schick E; Moessner E; Antony M; Stuchly T; Viert M; Hosse RJ; Freimoser-Grundschober A; Klein C; Schäfer M; Ritter M; Stubenrauch KG
    Front Immunol; 2024; 15():1406353. PubMed ID: 38881900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody.
    Xiang Y; Parng C; Olson K; Seletskaia E; Gorovits B; Jani D; Caiazzo T; Joyce A; Donley J
    AAPS J; 2019 Mar; 21(3):46. PubMed ID: 30927117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect assessment of neutralizing anti-drug antibodies utilizing pharmacokinetic assay data.
    Vettermann C; Ortiz J; Lee S; Sanchez S; Victor HP; Ma M; Heath T; Gupta S
    J Immunol Methods; 2016 Feb; 429():28-38. PubMed ID: 26711311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assay development considerations to improve drug tolerance in direct competitive ligand binding neutralizing antibody assays, pretreatment strategies.
    Rathi A; Rinker S; Niu H; Carter C; Kumar S; Cowan K
    J Immunol Methods; 2023 Jun; 517():113484. PubMed ID: 37116778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics.
    Wu B; Chung S; Jiang XR; McNally J; Pedras-Vasconcelos J; Pillutla R; White JT; Xu Y; Gupta S
    AAPS J; 2016 Nov; 18(6):1335-1350. PubMed ID: 27495119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing Domain Specificity in the Development of a Cell-Based Binding Assay for the Detection of Neutralizing Antibodies Against a CD47xPD-L1 Bispecific Antibody.
    Luong M; Wang Y; Donnelly BB; Lepsy C
    AAPS J; 2023 Sep; 25(6):91. PubMed ID: 37740131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of cell-based and non-cell-based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteins.
    Hu J; Wala I; Han H; Nagatani J; Barger T; Civoli F; Kaliyaperumal A; Zhuang Y; Gupta S
    J Immunol Methods; 2015 Apr; 419():1-8. PubMed ID: 25795420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity Assays.
    Dengler AF; Weiss R; Truong T; Irvin SC; Gadhia N; Hassanein M; Georgaros C; Taylor JA; Paccaly A; Sumner G; Andisik MD; Torri A; Partridge MA
    AAPS J; 2021 Oct; 23(6):109. PubMed ID: 34608545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment.
    Gouty D; Cai CC; Cai XY; Kasinath A; Kumar V; Alvandkouhi S; Yang J; Pederson S; Babbitt B; Peritt D; Rudy A; Koppenburg V; Dasilva A; Ullmann M; Liu S; Satterwhite C
    AAPS J; 2017 Dec; 20(1):25. PubMed ID: 29285735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
    Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T
    J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.